Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells.
Epigenetic anti-cancer drugs with demethylating effects have shown to alter genome organization in mammalian cell nuclei. The interest in the development of novel epigenetic drugs has increased the demand for cell-based assays to evaluate drug performance in pre-clinical studies. An imaging-based cytometrical approach that can measure demethylation effects as changes in the spatial nuclear distributions of methylated cytosine and global DNA in cancer cells is introduced in this paper. The cells were studied by immunofluorescence with a specific antibody against 5-methylcytosine (MeC), and 4,6-diamidino-2-phenylindole (DAPI) for delineation of methylated sites and global DNA in nuclei. In the preprocessing step the segmentation of nuclei in three-dimensional images (3-D) is followed by an automated assessment of nuclear DAPI/MeC patterns to exclude dissimilar entities. Next, low-intensity MeC (LIM) and low-intensity DNA (LID) sites of similar nuclei are localized and processed to obtain specific nuclear density profiles. These profiles sampled at half of the total nuclear volume yielded two parameters: LIM(0.5) and LID(0.5). The analysis shows that zebularine and 5-azacytidine-the two tested epigenetic drugs introduce changes in the spatial distribution of low-intensity DNA and MeC signals. LIM(0.5) and LID(0.5) were significantly different (p<0.001) in 5-azacytidine treated (n=660) and zebularine treated (n=496) vs. untreated (n=649) DU145 human prostate cancer cells. In the latter case the LIM sites were predominantly found at the nuclear border, whereas treated populations showed different degrees of increase in LIMs towards the interior nuclear space, in which a large portion of heterochromatin is located. The cell-by-cell evaluation of changes in the spatial reorganization of MeC/DAPI signals revealed that zebularine is a more gentle demethylating agent than 5-azacytidine. Measuring changes in the topology of low-intensity sites can potentially be a valuable component in the high-throughput assessment of demethylation and risk of chromatin reorganization in epigenetic-drug screening tasks.
Gertych
Arkadiusz
A
Translational Cytomics Group, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. gertycha@cshs.org
Farkas
Daniel L
DL
Tajbakhsh
Jian
J
D000970:Antineoplastic Agents / Q000494:pharmacology; D001374:Azacitidine / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000187:drug effects / Q000235:genetics; D003562:Cytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D003596:Cytosine / Q000378:metabolism; D019175:DNA Methylation / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000737:chemistry / Q000378:metabolism; D044127:Epigenesis, Genetic / Q000187:drug effects*; D005453:Fluorescence; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D007211:Indoles / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics*; D009690:Nucleic Acid Conformation / Q000187:drug effects*
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D007211:Indoles; C007293:DAPI; D003562:Cytidine; C009131:pyrimidin-2-one beta-ribofuranoside; D003596:Cytosine; D001374:Azacitidine
Curr Top Microbiol Immunol. 2000;249:135-64
10802943
Cell. 2007 Feb 23;128(4):683-92
17320506
Genome Res. 2009 Jun;19(6):959-66
19273618
J Cell Biol. 2007 May 7;177(3):401-11
17485486
Adv Cancer Res. 1998;72:141-96
9338076
Biotechniques. 2007 Jul;43(1 Suppl):25-30
17936939
PLoS Biol. 2005 May;3(5):e157
15839726
Med Hypotheses. 2009 Nov;73(5):770-80
19501473
Cytometry A. 2009 Jul;75(7):569-83
19459215
Nat Rev Drug Discov. 2006 Apr;5(4):343-56
16582878
Pathologica. 1995 Jun;87(3):286-99
8570289
Clin Cancer Res. 2005 Jun 15;11(12):4571-9
15958643
FEBS Lett. 1991 Jul 22;285(2):155-9
1855583
Cell Oncol. 2005;27(5-6):335-45
16373966
Exp Cell Res. 2000 Mar 15;255(2):229-37
10694438
Mol Cancer Ther. 2005 Oct;4(10):1505-14
16227399
J Cell Sci. 1999 Oct;112 ( Pt 19):3353-60
10504340
Annu Rev Med. 2008;59:267-80
17937590
Cancer Cell. 2004 Aug;6(2):151-8
15324698
Chromosome Res. 1996 Jun;4(4):271-6
8817066
Exp Cell Res. 2004 Dec 10;301(2):266-79
15530862
PLoS Comput Biol. 2007 Jul;3(7):e138
17676980
Cancer Res. 2006 Mar 1;66(5):2794-800
16510601
Pharmacol Ther. 1995 Jan;65(1):19-46
7536332
Ann N Y Acad Sci. 2005 Nov;1058:246-54
16394141
J Cell Sci. 2002 Dec 1;115(Pt 23):4597-605
12415004
Biochim Biophys Acta. 2009 Sep;1790(9):847-62
19364478
Cytometry. 1998 Feb 1;31(2):85-92
9482277
Biochem Soc Trans. 2004 Dec;32(Pt 6):910-2
15506921
J Natl Cancer Inst. 2003 Mar 5;95(5):399-409
12618505